Table 2 The data set is divided into training set and validation set
Variables | Total (n = 139) | Train (n = 98) | Validation (n = 41) | p |
|---|---|---|---|---|
IL18, n (%) | 1 | |||
Low | 90 (65) | 63 (64) | 27 (66) | |
High | 49 (35) | 35 (36) | 14 (34) | |
Age, n (%) | 0.734 | |||
~40 | 59 (42) | 43 (44) | 16 (39) | |
41~ | 80 (58) | 55 (56) | 25 (61) | |
Gender, n (%) | 0.869 | |||
Female | 71 (51) | 51 (52) | 20 (49) | |
Male | 68 (49) | 47 (48) | 21 (51) | |
Histologic_grade, n (%) | 0.836 | |||
G2 | 71 (51) | 49 (50) | 22 (54) | |
G3 | 68 (49) | 49 (50) | 19 (46) | |
Radiotherapy, n (%) | 1 | |||
NO | 46 (33) | 32 (33) | 14 (34) | |
YES | 93 (67) | 66 (67) | 27 (66) | |
Histological_type, n (%) | 0.53 | |||
Astrocytoma | 46 (33) | 35 (36) | 11 (27) | |
Oligoastrocytoma | 34 (24) | 22 (22) | 12 (29) | |
Oligodendroglioma | 59 (42) | 41 (42) | 18 (44) | |
Chr_1p_19q_codeletion, n (%) | 0.476 | |||
Codel | 38 (27) | 29 (30) | 9 (22) | |
Non-Codel | 101 (73) | 69 (70) | 32 (78) | |
IDH_status, n (%) | 1 | |||
Mutant | 109 (78) | 77 (79) | 32 (78) | |
WT | 30 (22) | 21 (21) | 9 (22) | |
MGMT_promoter_status, n (%) | 0.725 | |||
Methylated | 111 (80) | 77 (79) | 34 (83) | |
Unmethylated | 28 (20) | 21 (21) | 7 (17) | |
Chemotherapy, n (%) | 1 | |||
NO | 45 (32) | 32 (33) | 13 (32) | |
YES | 94 (68) | 66 (67) | 28 (68) | |
OS, n (%) | 0.504 | |||
Alive | 102 (73) | 74 (76) | 28 (68) | |
Dead | 37 (27) | 24 (24) | 13 (32) | |
OS. time, Median (Q1, Q3) | 21.7 (14.97, 40.7) | 20.27 (14.39, 38.57) | 30.27 (17.77, 48.97) | 0.036 |
